Celerion is the privately owned CRO formed through the acquisition of the development and regulatory services consultancy and early clinical development operations of MDS Pharma Services. The focus of the company is providing comprehensive early clinical research and bioanalytical services to the drug development community. Although the name of the company is new, Celerion is committed to the same
level of service excellence on which MDS Pharma Services built its reputation. Celerion is derived from the Latin celeritas meaning swiftness and speed. This word reflects one of our founding principles: to deliver services that enable clients to get products to market faster. It also underlies another key goal of the business: to assist clients in making informed go/no-go decisions on compounds in development as early as possible. Celerion's combination of experienced people, scientific excellence and state-of-the-art facilities strongly positions the company as an industry leader in the conduct of early clinical research and bioanalysis studies. Our breadth of service offerings include:
Clinical Research (first-in-man to proof-of-concept for healthy subjects and patients)
Clinical Pharmacology Scientific Services (Modeling and Simulation, Study Design and Protocol Development, Data Management, Biostatistics, PK/PD, Medical Writing and Reporting)
Bioanalytical Services (Discovery through late stage)
Early Cardiac Safety Services
Program Management
Regulatory Affairs
Drug Development Consultancy
